People · Operator
Named in public records as an officer, director or promoter · active 2018–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Generation Bio Co. | — | Biotechnology | Series D+ | $211.8M | $4.6B | 2018 |
| Chroma Medicine, Inc. | — | Biotechnology | Series D+ | $135.0M | $2.3B | 2023 |
CATHERINE STEHMAN-BREEN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside CATHERINE STEHMAN-BREEN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| BIHUA CHEN | 1 | 14 |
| Michael Kelly | 1 | 11 |
| Jeff Jonas | 1 | 5 |
| Mark Angelino | 1 | 4 |
| Vic Myer | 1 | 3 |
| Jason Rhodes | 1 | 3 |
| Donald Nicholson | 1 | 2 |
| Thomas Cahill | 1 | 2 |
| Gustav Christensen | 1 | 2 |
| Glenn Goddard | 1 | 1 |
| GEORGE GOLUMBESKI | 1 | 1 |
| BRETT KAPLAN | 1 | 1 |
| PAOLA POZZI | 1 | 1 |
| JEFF MARRAZZO | 1 | 1 |
| Anthony Quinn | 1 | 1 |
| Geoffrey McDonough | 1 | 1 |
| Charlie Rowland | 1 | 1 |
| Thomas Graney | 1 | 1 |
| Geoff McDonoughy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.